Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Shares Shorted: Short Interest Down 78.4% in October

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 3,004 shares, a decrease of 78.4% from the September 30th total of 13,919 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 19,959 shares, the days-to-cover ratio is presently 0.2 days.

Emmaus Life Sciences Trading Down 20.1%

EMMA opened at $0.05 on Tuesday. The company’s 50 day moving average is $0.05 and its 200-day moving average is $0.02. Emmaus Life Sciences has a 1-year low of $0.01 and a 1-year high of $0.09. The company has a market cap of $3.23 million, a P/E ratio of -0.51 and a beta of 9.73.

Emmaus Life Sciences (OTCMKTS:EMMA) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $6.32 million for the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc is a biopharmaceutical company focused primarily on developing and commercializing treatments for rare and serious diseases. The company’s best-known product is Endari (L-glutamine), an oral powder approved by the U.S. Food and Drug Administration to reduce the acute complications of sickle cell disease in adults and children aged five and older.

Historically, Emmaus has concentrated on therapies for sickle cell disease and other conditions with significant unmet medical needs.